Hyderabad-based contract research, development and manufacturing organization Sai Life Sciences Limited (BSE: 544306, NSE: SAILIFE) posted a 100 percent year-on-year increase in net profit for Q2 FY26, driven by strong demand for its integrated CRO and CDMO offerings, robust operational leverage, and expansion into high-margin scientific platforms.
For the quarter ended September 30, 2025, Sai Life Sciences Limited reported revenue from operations of ₹537 crore, reflecting a 36 percent increase compared to the same period last year. EBITDA rose 43 percent to ₹156 crore, with the EBITDA margin expanding to 29 percent. Profit after tax doubled to ₹84 crore, up from ₹42 crore in Q2 FY25, supported by margin tailwinds and strong performance across its core business verticals.
Over the first half of FY26, revenue surpassed ₹1,000 crore, with the company reporting ₹1,034 crore in total revenue from operations, marking a 53 percent year-on-year increase. The half-year EBITDA stood at ₹281 crore, up 101 percent over the previous year’s figure of ₹140 crore. Profit after tax during the same period surged more than four times to ₹144 crore, with the PAT margin improving to 14 percent from 4 percent in H1 FY25.
The consistent financial momentum highlights how Sai Life Sciences Limited is emerging as a significant player in India’s pharmaceutical outsourcing landscape, with strong traction from global biopharmaceutical clients seeking end-to-end scientific support.
What operational strengths are driving Sai Life Sciences’ margin expansion and earnings performance?
Sai Life Sciences Limited’s margin expansion in Q2 FY26 is rooted in both volume growth and operational efficiency. The company benefitted from improved plant utilization and tighter cost control, which supported a one percentage point increase in EBITDA margin compared to the same quarter in FY25.
The Hyderabad-based CRDMO firm recorded ₹112 crore in profit before tax for the quarter, more than double the ₹55 crore reported a year ago. This performance reflects not just increased business volumes but also deeper engagement in complex, higher-margin projects across late-stage development and commercial manufacturing.
Krishna Kanumuri, Managing Director and Chief Executive Officer of Sai Life Sciences Limited, stated that the performance was underpinned by consistent execution and expanding relationships with clients in both discovery and commercial supply. He added that continued traction in late-stage programs also played a significant role in delivering the strong quarterly growth.
Institutional observers are likely to interpret the results as a sign of platform maturity. With a balanced portfolio of projects across the value chain, Sai Life Sciences Limited appears well-positioned to handle variability in client pipelines while continuing to generate predictable earnings growth.
How is Sai Life Sciences Limited building scientific capabilities in peptides, ADCs, and oligonucleotide platforms?
A key part of the company’s recent transformation has involved investing in scientific infrastructure to support complex and emerging modalities. In Q2 FY26, Sai Life Sciences Limited extended its peptide capabilities beyond discovery to development and scale-up, strengthening its value proposition as a “follow-the-molecule” CDMO partner.
The company also successfully executed photo-flow chemistry at plant scale for a major pharmaceutical client, a milestone that positions it to win more work in photochemical synthesis, an area seeing increasing demand for environmentally friendly and efficient synthesis routes.
Sai Life Sciences Limited completed discovery-stage bioconjugation projects for antibody-drug conjugates and is currently building Occupational Exposure Band 6 labs to further strengthen its capabilities in both discovery and CMC (chemistry, manufacturing, and controls) for ADCs. In the oligonucleotide space, it is validating a phosphoramidite process for a commercial program, pointing to readiness in servicing a market that is witnessing strong biotech and RNA therapeutics interest.
These investments are part of a long-term strategy to deepen its scientific value chain and offer integrated, technology-led solutions in high-value outsourcing categories. With the global CDMO market for oligonucleotides and ADCs projected to grow at double-digit CAGR over the next five years, Sai Life Sciences Limited’s timing and positioning appear strategically sound.
How are compliance and global partnerships shaping client confidence and revenue continuity?
Sai Life Sciences Limited successfully cleared 35 customer audits and three regulatory inspections across its manufacturing and R&D units in the past 12 months, with no data integrity deviations or critical observations. This regulatory compliance track record supports client trust, especially for programs moving into pivotal and commercial phases where quality systems are paramount.
The company completed Phase 2 expansion of its vivarium facility at its Hyderabad R&D center, adding 12,000 square feet to take the total capacity to 27,000 square feet. The upgraded space enhances the company’s preclinical and assay capabilities, helping it provide a more comprehensive range of services under one roof.
In a bid to expand its global footprint, Sai Life Sciences Limited has partnered with United Kingdom-based Agility Life Sciences and Centrix Pharma to offer end-to-end chemistry, manufacturing, and control services. These include API development, drug product manufacturing, and first-in-human trials, and are particularly focused on accelerating early-stage programs from the United Kingdom and Europe.
Through such partnerships, the Indian CRDMO firm aims to broaden its exposure to international biotech pipelines while reinforcing its integrated service offering that connects discovery and commercial readiness.
How is Sai Life Sciences Limited balancing growth with capital discipline and ESG initiatives?
While continuing to scale up infrastructure and scientific capabilities, Sai Life Sciences Limited is maintaining financial prudence. In H1 FY26, the company incurred capital expenditure of ₹248 crore, with most of the investment directed toward expanding R&D capacity and upgrading technology platforms. Despite this investment cycle, operating profitability remains intact, suggesting efficient capital deployment.
Chief Financial Officer Siva Chittor noted that the company remains focused on capital efficiency, margin improvement, and long-term profitable growth. With a strong foundation and expanding scientific infrastructure, Sai Life Sciences Limited aims to position itself as a credible alternative to larger multinational CDMOs for global biopharma clients seeking agility and innovation.
On the sustainability front, the company reported that its near-term greenhouse gas emission reduction targets have been validated by the Science Based Targets initiative. It has also signed on to the United Nations Women’s Empowerment Principles, signaling a broader commitment to gender inclusion and responsible growth. These moves may improve Sai Life Sciences Limited’s ESG credentials in the eyes of institutional investors, particularly as sustainability-linked mandates continue to gain prominence in global fund flows.
What does the earnings outlook suggest for Sai Life Sciences Limited in the upcoming quarters?
Sai Life Sciences Limited remains optimistic about sustaining its growth momentum in the coming quarters. Management reiterated its strategic focus on responsible scaling, innovation-led differentiation, and deeper client collaborations. With investments in advanced modalities such as peptides, ADCs, and oligonucleotides already underway, the company expects to attract more clients with complex scientific needs.
Analysts covering the pharmaceutical services sector are likely to watch Sai Life Sciences Limited’s progress in converting developmental projects into long-term commercial supply agreements. They may also evaluate margin sustainability as newly expanded capabilities come online and begin contributing to revenue.
The company is scheduled to host its Q2 FY26 earnings call at 4:00 PM IST on November 7, 2025, where additional details about the client pipeline, order book composition, and future expansion plans are expected to be discussed.
For investors, the company’s combination of high revenue growth, margin expansion, and technology investments in high-growth areas presents a differentiated CRDMO play. If the current trend continues, Sai Life Sciences Limited could emerge as a mid-cap favorite among institutions looking for exposure to India’s growing pharmaceutical outsourcing opportunity.
Key takeaways: Sai Life Sciences Q2 FY26 earnings highlight profitable growth, modality expansion, and margin momentum
- Sai Life Sciences Limited posted a 100 percent year-on-year increase in Q2 FY26 net profit to ₹84 crore, driven by broad-based growth across CRO and CDMO services.
- Revenue from operations rose 36 percent year-on-year to ₹537 crore in Q2 FY26, while EBITDA increased 43 percent to ₹156 crore, with margins expanding to 29 percent.
- For H1 FY26, total revenue crossed ₹1,000 crore and profit after tax surged 414 percent year-on-year to ₹144 crore, reflecting sustained demand and improved operational leverage.
- The company advanced its scientific platforms, adding scale-up capabilities in peptides, completing plant-scale photo-flow chemistry, and initiating commercial-phase oligonucleotide process validation.
- Sai Life Sciences Limited also enhanced its antibody-drug conjugate capabilities by executing bioconjugation programs and investing in new high-containment labs for both discovery and CMC.
- It cleared 35 customer audits and three regulatory inspections with zero data integrity deviations, strengthening global client trust and regulatory credibility.
- International partnerships with Agility Life Sciences and Centrix Pharma in the United Kingdom expanded the company’s global reach in early development and CMC services.
- Capital expenditure of ₹248 crore in H1 FY26 focused on scaling R&D capacity and technological platforms, aligned with future growth in high-value therapeutic areas.
- ESG progress included validated GHG targets by the Science Based Targets initiative and adoption of the UN Women’s Empowerment Principles, reflecting a maturing sustainability posture.
- With its expanded capabilities, clean compliance record, and strong balance sheet, Sai Life Sciences Limited appears well-positioned for long-term, technology-led growth in the global CDMO market.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
